Literature DB >> 15164806

The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France.

B Detournay1, C Pribil, M Fournier, B Housset, G Huchon, D Huas, P Godard, C Voinet, I Chanal, Colette Jourdanne, I Durand-Zaleski.   

Abstract

OBJECTIVE: The main objective of the SCOPE study was to estimate the total direct medical costs of patients with treated chronic obstructive pulmonary disease (COPD) in France according to severity stages.
METHODS: Total medical resources consumption of a sample of COPD patients was collected over a 12-month period through a national physician survey (including both general practitioners and lung specialists). This survey was completed for 255 patients. Data were then extrapolated to all patients with diagnosed and treated COPD in France. Average total medical resources consumption of a COPD patient per year was 4366 euros. Among this cost 41% was directly related to COPD follow-up, 25% to COPD-related complications (mainly exacerbations), and 34% to other diseases. More than one-third of the total direct COPD cost was related to hospitalizations and 31% to drug consumption. COPD-related costs increased markedly with severity based on FEV1 (but data suggested the existence of a threshold effect). SCOPE data did not show any evidence of a significant relationship between direct medical cost and patient age, sex, addiction to tobacco, or duration of COPD. The total medical consumption of COPD patients in France was 3.5 billion euros and accounted for 3.5% of the total medical expenditures (prevalence of COPD was estimated 1.3% in the general population).
RESULTS: The SCOPE study revealed the high level of medical resources consumption of patients with COPD.
CONCLUSIONS: The burden of COPD itself and its complications appeared to be of considerable magnitude in France especially for severe COPD.

Entities:  

Mesh:

Year:  2004        PMID: 15164806     DOI: 10.1111/j.1524-4733.2004.72329.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  9 in total

1.  Postapproval Development Options in COPD: A Case Study in Value-Based Healthcare Systems.

Authors:  Michael F Murphy; Paola Antonini; Zhihong Vicki Lai
Journal:  Am Health Drug Benefits       Date:  2011-01

Review 2.  Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.

Authors:  Kokuvi Atsou; Christos Chouaid; Gilles Hejblum
Journal:  BMC Med       Date:  2011-01-18       Impact factor: 8.775

3.  Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998-2010.

Authors:  Anders Løkke; Ole Hilberg; Philip Tønnesen; Rikke Ibsen; Jakob Kjellberg; Poul Jennum
Journal:  BMJ Open       Date:  2014-01-06       Impact factor: 2.692

4.  Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France.

Authors:  Kokuvi Atsou; Perrine Crequit; Christos Chouaid; Gilles Hejblum
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

5.  Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.

Authors:  Faustine Dalon; Nicolas Roche; Manon Belhassen; Maëva Nolin; Hervé Pegliasco; Gaëtan Deslée; Bruno Housset; Philippe Devillier; Eric Van Ganse
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-08-20

6.  Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.

Authors:  Martine Hoogendoorn; Isaac Corro Ramos; Michael Baldwin; Laura Luciani; Cecile Fabron; Bruno Detournay; Maureen P M H Rutten-van Mölken
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-02-18

7.  Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.

Authors:  Margaret K Pasquale; Shawn X Sun; Frank Song; Heather J Hartnett; Stephen A Stemkowski
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-11-01

Review 8.  Optimizing economic outcomes in the management of COPD.

Authors:  Roberto Dal Negro
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

9.  The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean Health Insurance Review and Assessment Service data.

Authors:  JinHee Kim; Chin Kook Rhee; Kwang Ha Yoo; Young Sam Kim; Sei Won Lee; Yong Bum Park; Jin Hwa Lee; YeonMok Oh; Sang Do Lee; Yuri Kim; KyungJoo Kim; HyoungKyu Yoon
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-11-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.